• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤学单臂II期试验中配对失败时间的治疗效果评估。

Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology.

作者信息

Texier Matthieu, Rotolo Federico, Ducreux Michel, Bouché Olivier, Pignon Jean-Pierre, Michiels Stefan

机构信息

Biostatistics and Epidemiology Unit, Gustave Roussy, Université Paris-Saclay, 94805 Villejuif, France.

CESP INSERM U1018, Paris-Sud University, 94805 Villejuif, France.

出版信息

Comput Math Methods Med. 2018 Jan 11;2018:1672176. doi: 10.1155/2018/1672176. eCollection 2018.

DOI:10.1155/2018/1672176
PMID:29568321
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5820554/
Abstract

In early phase clinical trials of cytotoxic drugs in oncology, the efficacy is typically evaluated based on the tumor shrinkage. However, this criterion is not always appropriate for more recent cytostatic agents, and alternative endpoints have been proposed. The growth modulation index (GMI), defined as the ratio between the times to progression in two successive treatment lines, has been proposed for a single-arm phase II trials. The treatment effect is evaluated by estimating the rate of patients having a GMI superior to a given threshold. To estimate this rate, we investigated a parametric method based on the distribution of the times to progression and a nonparametric one based on a midrank estimator. Through simulations, we studied their operating characteristics and the impact of different design parameters (censoring, dependence, and distribution) on them. In these simulations, the nonparametric estimator slightly underestimated the rate and had slightly overconservative confidence intervals in some cases. Conversely, the parametric estimator overestimated the rate and had anticonservative confidence intervals in some cases. The nonparametric method appeared to be more robust to censoring than the parametric one. In conclusion, we recommend the nonparametric method, but the parametric method can be used as a supplementary tool.

摘要

在肿瘤学中细胞毒性药物的早期临床试验中,疗效通常根据肿瘤缩小情况进行评估。然而,该标准并不总是适用于最近的细胞生长抑制剂,因此有人提出了替代终点。生长调节指数(GMI)定义为两个连续治疗阶段进展时间的比值,已被用于单臂II期试验。通过估计GMI高于给定阈值的患者比例来评估治疗效果。为了估计这个比例,我们研究了一种基于进展时间分布的参数方法和一种基于中秩估计量的非参数方法。通过模拟,我们研究了它们的操作特性以及不同设计参数(删失、相关性和分布)对它们的影响。在这些模拟中,非参数估计量在某些情况下略微低估了比例,并且置信区间略微过于保守。相反,参数估计量在某些情况下高估了比例,并且置信区间过于宽松。非参数方法似乎比参数方法对删失更具稳健性。总之,我们推荐使用非参数方法,但参数方法可作为一种补充工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/374e/5820554/30c23b0577af/CMMM2018-1672176.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/374e/5820554/95d7cd6ba1ef/CMMM2018-1672176.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/374e/5820554/77214b834e91/CMMM2018-1672176.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/374e/5820554/30c23b0577af/CMMM2018-1672176.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/374e/5820554/95d7cd6ba1ef/CMMM2018-1672176.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/374e/5820554/77214b834e91/CMMM2018-1672176.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/374e/5820554/30c23b0577af/CMMM2018-1672176.003.jpg

相似文献

1
Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology.肿瘤学单臂II期试验中配对失败时间的治疗效果评估。
Comput Math Methods Med. 2018 Jan 11;2018:1672176. doi: 10.1155/2018/1672176. eCollection 2018.
2
Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint.用于具有生长调节指数 (GMI) 终点的 II 期肿瘤学试验的统计方法。
Contemp Clin Trials. 2011 Jan;32(1):99-107. doi: 10.1016/j.cct.2010.09.010. Epub 2010 Oct 13.
3
Estimating the distribution of ratio of paired event times in phase II oncology trials.估计II期肿瘤试验中成对事件时间比值的分布。
Stat Med. 2023 Feb 10;42(3):388-406. doi: 10.1002/sim.9622. Epub 2022 Dec 27.
4
Mixed response and time-to-event endpoints for multistage single-arm phase II design.多阶段单臂II期设计的混合反应和事件发生时间终点
Trials. 2015 Jun 4;16:250. doi: 10.1186/s13063-015-0743-9.
5
Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint.以疾病进展时间为主要终点的非细胞毒性抗癌药物的II期临床试验设计
Control Clin Trials. 2000 Aug;21(4):343-59. doi: 10.1016/s0197-2456(00)00058-1.
6
A computationally simple bivariate survival estimator for efficacy and safety.
Lifetime Data Anal. 2006 Sep;12(3):365-87. doi: 10.1007/s10985-006-9011-3. Epub 2006 Aug 18.
7
Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.单臂与随机化 II 期癌症临床试验中错误率的比较。
J Clin Oncol. 2010 Apr 10;28(11):1936-41. doi: 10.1200/JCO.2009.25.5489. Epub 2010 Mar 8.
8
STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.斯坦因:用于无缝I/II期临床试验的简单毒性和疗效区间设计。
Stat Med. 2017 Nov 20;36(26):4106-4120. doi: 10.1002/sim.7428. Epub 2017 Aug 7.
9
Optimizing randomized phase II trials assessing tumor progression.优化评估肿瘤进展的随机II期试验。
Contemp Clin Trials. 2007 Feb;28(2):146-52. doi: 10.1016/j.cct.2006.05.003. Epub 2006 May 19.
10
Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements.通过对连续肿瘤测量值进行建模,以最佳观察到的RECIST反应作为终点来改进II期肿瘤试验。
Stat Med. 2017 Dec 20;36(29):4616-4626. doi: 10.1002/sim.7453. Epub 2017 Aug 28.

引用本文的文献

1
The Growth Modulation Index (GMI) as an Efficacy Outcome in Cancer Clinical Trials: A Scoping Review with Suggested Reporting Guidelines.癌症临床试验中作为疗效指标的生长调节指数(GMI):一项带有建议报告指南的范围综述
Curr Oncol Rep. 2025 May;27(5):516-532. doi: 10.1007/s11912-025-01667-1. Epub 2025 Mar 29.
2
The Progression-Free-Survival Ratio in Molecularly Aided Tumor Trials: A Critical Examination of Current Practice and Suggestions for Alternative Methods.分子辅助肿瘤试验中的无进展生存比率:对当前实践的批判性审视及替代方法建议
Biom J. 2025 Feb;67(1):e70028. doi: 10.1002/bimj.70028.
3
How is overall survival assessed in randomised clinical trials in cancer and are subsequent treatment lines considered? A systematic review.

本文引用的文献

1
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.高通量基因组学与难治疗的晚期癌症的临床结局:MOSCATO 01 试验结果。
Cancer Discov. 2017 Jun;7(6):586-595. doi: 10.1158/2159-8290.CD-16-1396. Epub 2017 Apr 1.
2
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial.基于肿瘤分子谱的分子靶向治疗与常规治疗比较治疗难治性癌症患者的随机 II 期试验:来自 SHIVA 试验的交叉分析。
Ann Oncol. 2017 Mar 1;28(3):590-596. doi: 10.1093/annonc/mdw666.
3
癌症随机临床试验中如何评估总生存期,以及后续治疗线是否被考虑?系统评价。
Trials. 2023 Nov 6;24(1):708. doi: 10.1186/s13063-023-07730-1.
4
Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology.转移性癌症临床试验终点:利用个体参与者数据为未来试验方法学提供信息。
J Natl Cancer Inst. 2022 Jun 13;114(6):819-828. doi: 10.1093/jnci/djab218.
5
Community-driven development of a modified progression-free survival ratio for precision oncology.精准肿瘤学中改良无进展生存比的社区驱动式开发。
ESMO Open. 2019 Nov 13;4(6):e000583. doi: 10.1136/esmoopen-2019-000583. eCollection 2019.
6
Phase II trial design with growth modulation index as the primary endpoint.以生长调节指数为主要终点的II期试验设计。
Pharm Stat. 2019 Mar;18(2):212-222. doi: 10.1002/pst.1916. Epub 2018 Nov 20.
Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.
精准肿瘤学:加州大学圣地亚哥分校穆尔斯癌症中心的PREDICT经验。
Mol Cancer Ther. 2016 Apr;15(4):743-52. doi: 10.1158/1535-7163.MCT-15-0795. Epub 2016 Feb 12.
4
Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial.在分析一项结直肠癌随机试验时考虑连续的治疗线。
Eur J Cancer. 2013 May;49(8):1882-8. doi: 10.1016/j.ejca.2013.02.006. Epub 2013 Mar 13.
5
Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.替莫唑胺治疗复发性胶质母细胞瘤的疗效及安全性分析
Ann Oncol. 2013 Feb;24(2):537-542. doi: 10.1093/annonc/mds470. Epub 2012 Nov 1.
6
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.序贯与联合化疗治疗晚期结直肠癌(FFCD 2000-05):一项开放标签、随机、3 期临床试验。
Lancet Oncol. 2011 Oct;12(11):1032-44. doi: 10.1016/S1470-2045(11)70199-1. Epub 2011 Sep 6.
7
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.利用患者肿瘤的分子谱分析进行的初步研究,以寻找潜在的靶点并为其难治性癌症选择治疗方法。
J Clin Oncol. 2010 Nov 20;28(33):4877-83. doi: 10.1200/JCO.2009.26.5983. Epub 2010 Oct 4.
8
Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint.用于具有生长调节指数 (GMI) 终点的 II 期肿瘤学试验的统计方法。
Contemp Clin Trials. 2011 Jan;32(1):99-107. doi: 10.1016/j.cct.2010.09.010. Epub 2010 Oct 13.
9
Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials.敏感性分析在评估晚期肿瘤试验无进展生存期方面的作用。
J Clin Oncol. 2009 Dec 10;27(35):5958-64. doi: 10.1200/JCO.2009.22.4329. Epub 2009 Oct 13.
10
Impact of chemotherapy beyond the first line in patients with metastatic breast cancer.转移性乳腺癌患者一线治疗后化疗的影响。
Breast Cancer Res Treat. 2008 Jan;107(2):275-9. doi: 10.1007/s10549-007-9550-7. Epub 2007 Mar 23.